Genisphere's 3DNA® is a nanoscale, multivalent scaffold made from proprietary, synthetic DNA formed in a flexible, branched structure. The 3DNA® nanocarriers are engineered and crosslinked to form a stable architecture while maintaining the biocompatibility of the nucleic acid building blocks. The company's mission is to expand collaborative partnerships and utilize its longstanding nanotechnology expertise to enhance the human condition through new 3DNA-based therapeutics. With a focus on targeted drug delivery and a history of successful collaborations, Genisphere is well-positioned to make significant contributions to the advancement of therapeutic technology in the biotechnology and healthcare industries.
Genisphere
3DNA® nanotechnology platform for targeted drug delivery
Founded 1997
8 employees
Venture round
Total: $6.00M
Biotechnology, Health Care
General Information
Company Name
Genisphere
Founded Year
1997
Employees
8
Industries
Biotechnology, Health Care
Funding Stage
Venture round
BounceWatch is an independent company data service, not affiliated with Genisphere. To contact Genisphere, visit genisphere.com.
Is this your company?
Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.
Get Verified
How does Genisphere compare?
A PDF of Genisphere and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.
This takes a few seconds: we look beyond our own index too.
Meeting Genisphere soon?
A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample
Discover More
About Genisphere
Business keywords: nanotechnology, drug delivery, 3DNA platform, biocompatibility, multivalent targeting, IP protection, collaborative partnerships, pharmaceutical, therapeutics, nanocarriers, lead programs, molecular entities, synthetic DNA, biologics
Funding Rounds & Investors (2)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| Venture Round | $4.00M | - |
|
01 Oct 2015 |
| Venture Round | $2.00M | - |
|
16 Sep 2014 |
Genisphere Alternatives & Competitors
View All Alternatives
Genisphere vs
Code Biotherapeutics
United States
Pioneering targeted delivery of precision genetic medicines
Series A
23 employees
Biotechnology, Health Care
Genisphere vs
CHAIN Biotechnology Ltd
United Kingdom
Superior and effective microbiome therapeutics
Seed
8 employees
Biotechnology, Health Care
Genisphere vs
SteadyMed Therapeutics
United States
SteadyMed Therapeutics, Inc. is a Specialty Pharmaceutical Company. SteadyMed leverages its PatchPum...
Post-IPO Equity
8 employees
Biotechnology, Health Care
FAQ About Genisphere
3DNA® nanotechnology platform for targeted drug delivery
Genisphere was founded in 1997.
Genisphere operates in Biotechnology and Health Care. Its work centres on nanotechnology, drug delivery, 3DNA platform and biocompatibility.
Genisphere has approximately 8 employees.
Genisphere has completed 2 funding rounds, raising a total of $6.00M. The latest funding stage is Venture round.
Top alternatives and competitors to Genisphere include Code Biotherapeutics, CHAIN Biotechnology Ltd, SteadyMed Therapeutics, Acthera Therapeutics Ltd., Pneuma Respiratory, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Genisphere and Code Biotherapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.
Source: BounceWatch company record for Genisphere, https://bouncewatch.com/company/genisphere, updated 20 December 2024. When citing, please name BounceWatch and link this page.
